OCT West Coast 2025: Patient and site centricity go hand-in-hand
By designing site-centric trials, sponsors can ensure their clinical trials also become patient-centric, said an expert at a conference. It is …
By designing site-centric trials, sponsors can ensure their clinical trials also become patient-centric, said an expert at a conference. It is …
GlobalData estimates that by the end of 2024, there will be around 14.50 million diagnosed prevalent cases of men and …
TC BioPharm has completed subject dosing in Cohort A of the Phase IIb ACHIEVE trial of TCB008 in the UK, …
With 2025 well underway, the runaway momentum of artificial intelligence (AI) looks unstoppable. GlobalData estimates that the total AI market …
Johnson and Johnson (J&J) has announced the cancellation of its Phase III E.mbrace study examining Sanofi’s investigational vaccine for extraintestinal …
Johnson and Johnson (J&J) has announced the cancellation of its Phase III E.mbrace study examining Sanofi’s investigational vaccine for extraintestinal …
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, for treating venous …
A once-weekly injection of semaglutide could cut alcohol cravings and reduce the amount someone living with alcohol use disorder (AUD) …
Selkirk Pharma has introduced a paradigm-shifting service, ClinFAST, for ensuring rapid small-volume clinical study materials delivery. The service is designed to …
Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as …
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses …
China has seen a rise in ongoing clinical trials for the past few years which has now surpassed the US, …
US-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III …
GenSight’s gene therapy treatment for patients living with Leber hereditary optic neuropathy (LHON) has demonstrated sustained efficacy and eyesight improvement …
US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating Fragile X …